"description","uuid:ID","instanceType","id","name","label","rationale"
"The main design for the study","68c399cb-29d4-4655-98df-a60d3bccfa26","StudyDesign","StudyDesign_1","Study Design 1","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
